{"organizations": [], "uuid": "f9077fe52f9b6e8b1ae0d058b8fffd21ed857139", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/06/pr-newswire-celgene-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds-investors-with-losses-in-excess-of.html", "country": "US", "domain_rank": 767, "title": "CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-07T06:50:00.000+03:00", "replies_count": 0, "uuid": "f9077fe52f9b6e8b1ae0d058b8fffd21ed857139"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/06/pr-newswire-celgene-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-reminds-investors-with-losses-in-excess-of.html", "ord_in_thread": 0, "title": "CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG", "locations": [], "entities": {"persons": [{"name": "charles c. foti", "sentiment": "none"}, {"name": "jr.", "sentiment": "none"}, {"name": "lewis kahn", "sentiment": "none"}], "locations": [{"name": "new orleans", "sentiment": "none"}, {"name": "louisiana", "sentiment": "none"}, {"name": "united states district court", "sentiment": "none"}, {"name": "louisiana", "sentiment": "none"}, {"name": "new jersey", "sentiment": "none"}], "organizations": [{"name": "lead plaintiff deadline in class action lawsuit against celgene corporation", "sentiment": "neutral"}, {"name": "kahn swick & foti", "sentiment": "neutral"}, {"name": "celgene", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}, {"name": "celgene corporation", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW ORLEANS, April 6, 2018 /PRNewswire/ -- Kahn Swick & Foti, LLC (\"KSF\") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 29, 2018 to file lead plaintiff applications in a securities against Celgene Corporation (NasdaqGS: CELG), if they purchased the Company's shares between September 12, 2016 and February 27, 2018, inclusive (the \"Class Period\"). This action is pending in the United States District Court for the District of New Jersey.\nWhat You May Do\nIf you purchased shares of Celgene and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( lewis.kahn@ksfcounsel.com ), or visit https://www.ksfcounsel.com/cases/nasdaqgs-celg/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 29, 2018 .\nAbout the Lawsuit\nCelgene and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.\nOn October 19, 2017, the Company disclosed that it was discontinuing trials of its long-touted drug GED-0301 and recording a $1.6 billion impairment charge due to the drug's failure. Then, on February 27, 2018, the Company revealed that the U.S. Food and Drug Administration had issued a refusal-to-file letter rejecting the New Drug Application (\"NDA\") for Ozanimod, another of its leading drug candidates, because \"the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review.\"\nOn this news, the price of Celgene's shares plummeted.\nAbout Kahn Swick & Foti, LLC\nKSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.\nTo learn more about KSF, you may visit www.ksfcounsel.com .\nContact:\nKahn Swick & Foti, LLC\nLewis Kahn, Managing Partner\nlewis.kahn@ksfcounsel.com\n1-877-515-1850\n206 Covington St.\nMadisonville, LA 70447\nView original content with multimedia: http://www.prnewswire.com/news-releases/celgene-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick--foti-llc-reminds-investors-with-losses-in-excess-of-1 -of-lead-plaintiff-deadline-in-class-action-lawsuit-against-celgene-corporation---celg-300625803.html\nSOURCE Kahn Swick & Foti, LLC", "external_links": ["https://www.ksfcounsel.com/cases/nasdaqgs-celg/", "http://www.ksfcounsel.com/", "http://www.prnewswire.com/news-releases/celgene-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick--foti-llc-reminds-investors-with-losses-in-excess-of-100000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-celgene-corporation---celg-300625803.html"], "published": "2018-04-07T06:50:00.000+03:00", "crawled": "2018-04-07T07:22:24.026+03:00", "highlightTitle": ""}